PSPaulo Jacob Silva

Paulo Jacob Silva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Paulo Jacob Silva has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Proline stabilizes amphiphilic gold nanoparticles via hydrophobic interactions

    by Ting Mao, Quy Ong, Joachim Kohlbrecher, Ekaterina Poliukhina, Paulo Jacob Silva, Francesco Stellacci

    Colloidal dispersions are key in many fields of science and technology. Recently, we have shown that small molecules can stabilize dispersions of nanoscale objects, such as proteins and nanoparticles by screening their net attractive interactions. This new effect is essentially the opposite of the well-known salt screening of electrostatic interaction. Here we show that small molecule stabilization of nanoparticles is a phenomenon strongly linked to the hydrophobic content of the particles as well as to the strength of their hydrophobic attraction. We compare the effect of proline on gold nanoparticles coated with 11-mercaptoundecane sulfonate (MUS) at varying percentages of the hydrophobic ligand octanethiol (OT). We show that the larger the percentage of OT, the larger the proline stabilization effect is. We also compare the effect of proline on water dispersions of nanoparticles with that on heavy water dispersions. In the latter, the hydrophobic effect plays a bigger role. We find that in D2O, proline stabilization is larger. We also compare the effect of proline on the same MUS:OT gold nanoparticles before and after an annealing process that is known to render the particle more hydrophilic. Proline is more effective on the particles before annealing. Finally, we study the effect of proline on non-aggregating allMUS nanoparticles. We find that proline stabilization of these particles is mainly due to a reduction in the long-range attraction coefficient. Overall, we show that proline stabilizes nanoparticle dispersions more effectively as the hydrophobic attraction between nanoparticles increases.


  • Open Access

    A pan-respiratory virus attachment inhibitor with high potency in human airway models and in vivo

    by Gregory Mathez, Paulo Jacob Silva, Vincent Carlen, Charlotte Deloizy, Clémentine Prompt, Anaïs Hubart, Joana Rocha-Pereira, Marie Galloux, Ronan Le Goffic, Francesco Stellacci, et al.

    Respiratory viruses can cause severe infections, often leading to hospitalization or death, and pose a major pandemic threat. No broad-spectrum antiviral is currently available. However, most respiratory viruses use sialic acid or heparan sulfates as attachment receptors. Here, we report the identification of a pan-respiratory antiviral strategy based on mimicking both glycans. We synthesized a modified cyclodextrin that simultaneously mimics heparan sulfate and sialic acid. This compound demonstrated broad-spectrum antiviral activity against important human pathogens: parainfluenza virus 3, respiratory syncytial virus, influenza virus H1N1, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In addition, the compound is active against avian strains of influenza virus, revealing its importance for pandemic preparedness. The compound retains broad-spectrum activity in ex vivo models of respiratory tissues and in vivo against respiratory syncytial virus and influenza virus, using prophylactic and therapeutic strategies. These findings contribute to the development of future treatments and preventive measures for respiratory viral infections.


  • Open Access

    Influenza A(H1N1)pdm09 virus resistance to baloxavir, oseltamivir and sialic acid mimetics in single and dual therapies: Insights from human airway epithelia and murine models

    by Clément Fage, Sheryline Loison, Arnaud Charles-Antoine Zwygart, Romain Poli, Stéphane Rosset, Chiara Medaglia, Mathieu Hubert, Patricia Suter-Boquete, Oscar Vadas, Song Huang, et al.


  • Open Access

    A pan-respiratory virus attachment inhibitor with high potency in human airway models and in vivo

    by Gregory Mathez, Paulo Jacob Silva, Vincent Carlen, Charlotte Deloizy, Clémentine Prompt, Anaïs Hubart, Joana Rocha-Pereira, Marie Galloux, Ronan Le Goffic, Francesco Stellacci, et al.

    Respiratory viruses can cause severe infections, including bronchiolitis and pneumonia, often leading to hospitalization or death. Due to their ease of transmission, they are also scrutinized for their pandemic potential. No broad-spectrum antiviral is currently available. However most respiratory viruses use sialic acid or heparan sulfates as attachment receptors. Here, we report the identification of a pan-respiratory antiviral strategy based on mimicking both glycans. We synthesized and characterized a unique modified cyclodextrin that simultaneously mimics heparan sulfate and sialic acid. This novel compound demonstrated broad-spectrum antiviral activity against important human pathogens: parainfluenza virus 3, respiratory syncytial virus, influenza virus H1N1, SARS-CoV-2. Additionally, the compound is active against different avian strains of influenza virus, revealing its importance for pandemic preparedness. The compound retains broad- spectrum activity in ex vivo models of respiratory tissues and in vivo experiments against RSV and Influenza virus, using both prophylactic and therapeutic strategies. These findings represent a significant step forward in the development of future treatments and preventive measures for respiratory viral infections. Significance Statement Following the SARS-CoV-2 pandemic, Influenza A H5N1 has become widespread in poultry and has already begun to spill over into mammals, posing a potential risk for the next pandemic. Indeed, respiratory viruses represent a major threat for future global health crises. Unfortunately, there is a significant lack of broad-spectrum antivirals available for such scenarios. To address this gap, our study developed a single molecule with the capacity to inhibit a wide range of clinically relevant human respiratory viruses including avian strains of influenza virus. This antiviral demonstrated verified efficacy not only in cellular systems but also in human-derived respiratory tissues and animal models.